View Older Stories View More Recent Stories
-
Terns Pharmaceuticals (TERN) PT Raised to $54 at Mizuho
-
Terns Pharmaceuticals (TERN) PT Raised to $60 at H.C. Wainwright
-
Terns Pharmaceuticals Inc. (TERN) files mixed shelf
-
BMO Capital Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Raised to $58 at Oppenheimer
-
Terns Pharmaceuticals Inc. (TERN) Halted, News Pending
-
Terns Pharmaceuticals Inc. (TERN) halted, news pending
-
These stocks are new additions to Mizuho's 'Americas Top Picks' list
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Raised to $35 at Citizens: Becoming Best-in-Class
-
Terns Pharmaceuticals (TERN) PT Raised to $35 at Truist Securities
-
Terns Pharmaceuticals (TERN) PT Raised at BMO Capital on 'Strong ASH Data'
-
H.C. Wainwright Upgrades Terns Pharmaceuticals (TERN) to Buy
-
Terns Pharmaceuticals (TERN) PT Raised to $28 at Truist Securities
-
Terns Pharmaceuticals (TERN) PT Raised to $24 at Oppenheimer
-
William Blair Upgrades Terns Pharmaceuticals (TERN) to Outperform
-
Terns presents positive TERN-701 data at ASH meeting
-
H.C. Wainwright Reiterates Neutral Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Lowered to $15 at Citizens After TERN-601 Development Stopped
-
Terns Pharmaceuticals (TERN) PT Lowered to $17 at Oppenheimer
-
After-hours movers: Netflix, Intuitive Surgical, DraftKings, Texas Instruments
-
Truist Securities Starts Terns Pharmaceuticals (TERN) at Buy
-
Citizens Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Barclays Starts Terns Pharmaceuticals (TERN) at Overweight
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals Inc. (TERN) Presents Positive Data from Phase 1 Study of TERN-601
-
Citizens JMP Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Lowered to $15 at BMO Capital
-
Terns Pharmaceuticals, Inc. (TERN) Tops Q1 EPS by 4c
-
Citizens JMP Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals, Inc. (TERN) Tops Q4 EPS by 6c
-
Will Pfizer step into the obesity ring? Wolfe Research answers
-
Terns Pharmaceuticals (TERN) Provides Program Updates
-
Terns Pharmaceuticals Inc. (TERN) Appoints Andrew Gengos as CFO
-
Oppenheimer Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Raised to $20 at Oppenheimer
-
Terns Pharmaceuticals Inc. (TERN) Reports Positive Early Data from Phase 1 CARDINAL Trial of TERN-701
-
Terns Pharmaceuticals Inc. (TERN) Appoints Heather Turner to its Board
-
Terns Pharmaceuticals (TERN) PT Raised to $7.50 at H.C. Wainwright
-
Oppenheimer Starts Terns Pharmaceuticals (TERN) at Outperform
-
Terns Pharmaceuticals (TERN) PT Raised to $14 at Mizuho
-
Terns Pharmaceuticals Inc. (TERN) Prices Upsized 11.92M Share Offering at $10.50/sh
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals Inc. (TERN) Announces Proposed $125M Share Offering
-
Terns Pharmaceuticals (TERN) PT Raised to $30 at Jefferies Following +16% Gain Today
-
Terns Pharmaceuticals Inc. (TERN) Climbs 29% Following Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
-
Terns Pharmaceuticals (TERN) Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
-
TD Cowen Reiterates Buy Rating on Terns Pharmaceuticals (TERN)
-
Mizuho Adds New Names to Top Pick List

